title: Olanzapine-induced rhabdomyolysis.
abstract: OBJECTIVE
  To report a possible case of olanzapine-induced rhabdomyolysis with concomitant lithium-induced pseudo-infarction electrocardiogram changes.
  
  
  METHODS
  A 13-year-old white boy was admitted to the hospital with profound weakness and electrocardiogram (EGG) changes suggestive of myocardial damage after starting olanzapine and lithium. An adverse medication effect was not considered at the time of the patient's admission. The time course of onset of weakness was coincident with administration of olanzapine. ECG abnormalities are a known manifestation of lithium therapy
  
  
  CONCLUSIONS
  This is a case description of olanzapine-induced rhabdomyolysis. Although other antipsychotic agents have been reported to cause rhabdomyolysis, an adverse drug reaction was not initially part of this patient's differential diagnosis. The patient had begun reporting rnyalgias six days after starting olanzapine. Fourteen days later, these symptoms forced him to bed rest; lithium was added for behavior misinterpreted as disobedience and oppositional disorder. Only when medications were considered as cause of the weakness and EGG changes, was the true nature of the patient's illness discovered.
  
  
  CONCLUSIONS
  Olanzapine, like other neuroleptic agents, can cause rhabdomyolysis. Lithium can cause multiple EGG changes that can be misinterpreted as myocardial damage. Medication effects and adverse effects must always be considered in any disease complex.
authors.affiliation: Division of Clinical Pharmacology, Georgetown University Medical Center, Washington, DC 20007-2195, USA. Rosebra@aol.com
authors.forename: C J
authors.initials: CJ
authors.lastname: Rosebraugh
authors.forename: D A
authors.initials: DA
authors.lastname: Flockhart
authors.forename: S U
authors.initials: SU
authors.lastname: Yasuda
authors.forename: R L
authors.initials: RL
authors.lastname: Woosley
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D003937:Diagnosis, Differential; D004562:Electrocardiography / Q000187:drug effects*; D006801:Humans; D008094:Lithium / Q000009:adverse effects*; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D008094:Lithium; D000077152:Olanzapine